文献速递炎症性肠病消化道肿瘤与早癌

产干扰素γ的CD8+组织驻留记忆T细胞是免疫检查点抑制剂结肠炎的可靶向标志

Interferon-Gamma-Producing CD8+ Tissue Resident Memory T Cells Are a Targetable Hallmark of Immune Checkpoint Inhibitor-Colitis.
PubMed 文献 · Gastroenterology · 2021-06-17

本研究采用横断面和纵向设计,比较ICI结肠炎、ICI无结肠炎、溃疡性结肠炎和健康对照,发现CD8+组织驻留记忆T细胞是ICI结肠炎主要活化T细胞亚群,其活化与临床及内镜严重度相关,且高表达干扰素γ,用JAK抑制剂托法替尼成功治疗一例难治性患者。

要点

  • CD8+TRM细胞是ICI结肠炎主要活化T细胞亚群,与病情严重度相关。
  • ICI结肠炎免疫病理与溃疡性结肠炎不同,CD8+TRM高表达干扰素γ。
  • 托法替尼成功靶向该通路治疗难治性ICI结肠炎。

核心结论

  • 产干扰素γ的CD8+TRM细胞是ICI结肠炎的病理标志和新的治疗靶点。

研究设计与样本

  • 横断面研究比较ICI结肠炎、ICI无结肠炎、溃疡性结肠炎和健康对照,部分ICI结肠炎患者纵向随访。
  • 采用多参数和光谱流式细胞术、光谱免疫荧光显微镜、靶向基因面板及批量和单细胞RNA测序。

主要发现

  • CD8+TRM细胞是ICI结肠炎中主要活化的T细胞亚群。
  • ICI结肠炎胃肠道免疫病理在免疫和上皮信号水平与溃疡性结肠炎不同。
  • CD8+TRM细胞活化与ICI结肠炎临床和内镜严重度相关。
  • 单细胞RNA测序显示ICI结肠炎中活化CD8+TRM细胞高表达检查点抑制剂和干扰素γ转录本。
  • 抗CTLA-4/PD-1联合治疗和抗PD-1相关结肠炎中均见类似发现。

临床怎么用

  • 基于数据使用JAK抑制剂托法替尼成功靶向该通路治疗一例难治性ICI结肠炎患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: The pathogenesis of immune checkpoint inhibitor (ICI)-colitis remains incompletely understood. We sought to identify key cellular drivers of ICI-colitis and their similarities to idiopathic ulcerative colitis, and to determine potential novel therapeutic targets. METHODS: We used a cross-sectional approach to study patients with ICI-colitis, those receiving ICI without the development of colitis, idiopathic ulcerative colitis, and healthy controls. A subset of patients with ICI-colitis were studied longitudinally. We applied a range of methods, including multiparameter and spectral flow cytometry, spectral immunofluorescence microscopy, targeted gene panels, and bulk and single-cell RNA sequencing. RESULTS: We demonstrate CD8+ tissue resident memory T (TRM) cells are the dominant activated T cell subset in ICI-colitis. The pattern of gastrointestinal immunopathology is distinct from ulcerative colitis at both the immune and epithelial-signaling levels. CD8+ TRM cell activation correlates with clinical and endoscopic ICI-colitis severity. Single-cell RNA sequencing analysis confirms activated CD8+ TRM cells express high levels of transcripts for checkpoint inhibitors and interferon-gamma in ICI-colitis. We demonstrate similar findings in both anti-CTLA-4/PD-1 combination therapy and in anti-PD-1 inhibitor-associated colitis. On the basis of our data, we successfully targeted this pathway in a patient with refractory ICI-colitis, using the JAK inhibitor tofacitinib. CONCLUSIONS: Interferon gamma-producing CD8+ TRM cells are a pathological hallmark of ICI-colitis and a novel target for therapy.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Sasson SC, Slevin SM, Cheung VTF, et al. Interferon-Gamma-Producing CD8+ Tissue Resident Memory T Cells Are a Targetable Hallmark of Immune Checkpoint Inhibitor-Colitis. Gastroenterology. 2021. PMID: 34147519. doi:10.1053/j.gastro.2021.06.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。